We Offer Worldwide Shipping
Login Wishlist



  • Brand : BIOFRON

  • Catalogue Number : BF-H2010

  • Specification : 98%

  • CAS number : 35354-74-6

  • Formula : C18H18O2

  • Molecular Weight : 266.33

  • PUBCHEM ID : 72303

  • Volume : 20mg

In stock

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight



Colorless granular crystallization

Botanical Source

Aconitum carmichaelii,Clausena emarginata,Elephantopus tomentosus,Manglietia fordiana,Pothos chinensis

Structure Type



Standards;Natural Pytochemical;API




3',5-Di-2-propenyl-[1,1'-biphenyl]-2,4'-diol/5,3'-DIALLYL-2,4'-DIHYDROXYBIPHENYL/3,3'-DIALLYL-4,6'-DIHYDROXYBIPHENYL/HONEYSUCKLEFLOWEREXTRACT/5,3'-diallyl-biphenyl-2,4'-diol/Honokiol/[1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl-/2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol/3',5-Diallyl-2,4'-dihydroxybiphenyl/5,3'-DIALLYL-2,4'-DIHYDROXYDIPHENYL/3',5-Diallylbiphenyl-2,4'-diol/5,5'-diallyl-2,4'-dihydroxybiphenyl/3',5-Diallyl-2,4'-biphenyldiol




1.1±0.1 g/cm3



Flash Point

184.0±21.9 °C

Boiling Point

400.1±40.0 °C at 760 mmHg

Melting Point



InChl Key

WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:35354-74-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate




Background: Honokiol ((3′,5-di-(2-propenyl)-1,1′-biphenyl-2,2′-diol), a lignan, is a promising antitumor compound, having exerted activity against a number of human cancer cell lines. Honokiol has inhibitory role on the proliferation, invasion and survival of cancer cells in in vitro as well as in vivo studies. It interferes with signaling pathways components in order to elicit the anticancer effect.
Scope and approach: In present review, the published data on the efficacy of honokiol against various cancer cell lines and tumor-bearing animal models has been presented and discussed.
Key findings and conclusions: Honokiol lowers the expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 methyltransferase among numerous other anticancer functions. It increases bone morphogenetic protein 7 (BMP7), Bax protein, among others. It does so by interfering with the major checkpoints such as nuclear factor kappa B (NF-κB), and activator of transcription 3 (STAT3), mammalian target of rapamycin (m-TOR), epidermal growth factor receptor (EGFR), Sonic hedgehog (SHH). It promotes the efficacy of several anticancer drugs and radiation tolerance. The derivatization of honokiol results in compounds with interesting attributes in terms of cancer control. This review will shed light on the scopes and hurdles in the relevance of the bioactive lignan honokiol in cancer management.


Breast cancer; Honokiol; Ovarian and lung cancer; Prostate cancer; Signaling pathways.


Honokiol: An Anticancer Lignan


Abdur Rauf 1 , Seema Patel 2 , Muhammad Imran 3 , Aneela Maalik 4 , Muhammad Umair Arshad 5 , Farhan Saeed 5 , Yahia N Mabkhot 6 , Salim S Al-Showiman 6 , Nazir Ahmad 5 , Eman Elsharkawy 7

Publish date

2018 Nov




Honokiol is a natural product and an emerging drug for a wide variety of malignancies, including hematopoietic malignancies, sarcomas, and common epithelial tumors. The broad range of activity of honokiol against numerous malignancies with diverse genetic backgrounds suggests that honokiol is inhibiting an activity that is common to multiple malignancies. Oncogenic transcription factor FOXM1 is one of the most overexpressed oncoproteins in human cancer. Here we found that honokiol inhibits FOXM1-mediated transcription and FOXM1 protein expression. More importantly, we found that honokiol’s inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1. This binding is specific to honokiol, a dimerized allylphenol, and was not observed in compounds that either were monomeric allylphenols or un-substituted dihydroxy phenols. This indicates that both substitution and dimerization of allylphenols are required for physical interaction with FOXM1. We thus demonstrate a novel and specific mechanism for FOXM1 inhibition by honokiol, which partially may explain its anticancer activity in cancer cells.


Breast cancer; Honokiol; Ovarian and lung cancer; Prostate cancer; Signaling pathways.


Honokiol Is a FOXM1 Antagonist


Marianna Halasi 1 , Ben Hitchinson 2 , Binal N Shah 1 , Renata Varaljai 2 , Irum Khan 1 , Elizaveta V Benevolenskaya 2 , Vadim Gaponenko 2 , Jack L Arbiser 3 , Andrei L Gartel 4 5

Publish date

2018 Jan 24




Osteosarcoma is the most common primary malignant tumor of bone, the long-term survival of which has stagnated in the past several decades. In the present study, we investigated the anticancer effect of honokiol (HNK), an active component isolated and purified from the magnolia officinalis on human osteosarcoma cells. Our results showed that honokiol caused dose-dependent and time-dependent cell death in human osteosarcoma cells. The types of cell death induced by honokiol were primarily autophagy and apoptosis. Furthermore, honokiol induced G0/G1 phase arrest, elevated the levels of glucose-regulated protein (GRP)-78, an endoplasmic reticular stress (ERS)-associated protein, and increased the production of intracellular reactive oxygen species (ROS). In contrast, reducing production of intracellular ROS using N-acetylcysteine, a scavenger of ROS, concurrently suppressed honokiol-induced cellular apoptosis, autophagy, and cell cycle arrest. Consequently, honokiol stimulated phosphorylation of extracellular signal-regulated kinase (ERK)1/2. Furthermore, pretreatment of osteosarcoma cells with PD98059, an inhibitor of ERK1/2, inhibited honokiol-induced apoptosis and autophagy. Finally, honokiol suppressed tumor growth in the mouse xenograft model. Taken together, our results revealed that honokiol caused G0/G1 phase arrest, induced apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells. Honokiol is therefore a promising candidate for development of antitumor drugs targeting osteosarcoma.


Honokiol Induces Apoptosis and Autophagy via the ROS/ERK1/2 Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo


Kangmao Huang 1 , Yanyan Chen 2 , Rui Zhang 3 , Yizheng Wu 1 , Yan Ma 1 , Xiangqian Fang 4 , Shuying Shen 5

Publish date

2018 Feb

Description :

Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.